April 19, 2021
United Therapeutics Announces Submission of Tyvaso DPI™ New Drug Application to FDA
READ MORE
April 1, 2021
United Therapeutics Announces Fda Approval And Launch Of Tyvaso® For The Treatment Of Pulmonary Hypertension Associated With Interstitial Lung Disease
READ MOREJanuary 13, 2021
United Therapeutics Announces New England Journal Of Medicine Publication Of The Increase Study Evaluating Tyvaso® In Pulmonary Hypertension Associated With Interstitial Lung Disease
READ MORE© Copyright 2021 United Therapeutics Corporation | All rights reserved. | US-CORP-0173 UTHR
WHO Group 1 pulmonary hypertension is also known as pulmonary arterial hypertension (PAH) and is distinguished by high blood pressure that specifically occurs in the vessels that supply the lungs. This is distinct from more generalized hypertension which is characterized by high blood pressure in vessels throughout the body. In PAH, the blood vessels in the lung stiffen and become narrower, which increases the pressure in the arteries and causes the heart to pump harder in order to pass blood through them. Over time, the added stress from heightened blood pressure in the lungs can cause the heart to weaken. Patients with PAH commonly experience symptoms such as shortness of breath, fatigue, chest pain, dizziness and/or fainting. These patients can also experience difficulties in completing normal activities such as climbing stairs.
